Clinical Review of Current Techniques of Magnetic Resonance Imaging of Atherosclerosis

Joy Cambe1, Sylvia Biso1,3*, Nadia Alie1 and Venkatesh Mani1,2

1Translational and Molecular Imaging Institute, Icahn School of Medicine at Mt. Sinai, New York, New York, 10029, USA
2Department of Radiology, Icahn School of Medicine at Mt. Sinai, New York, New York, 10029, USA
3Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA

Abstract

Cardiovascular disease (CVD), notably atherosclerosis, is the leading cause of morbidity and mortality worldwide, commonly caused by thrombotic occlusion of a vulnerable plaque. Early assessment of atherosclerotic lesions is an important diagnostic goal in order to decrease the coronary artery disease burden. The purpose of this article is to review current MRI techniques on atherosclerosis and explore their clinical applications. First, this article will review the pathogenesis of atherosclerosis and describe various vulnerable plaque features i.e. intraplaque hemorrhage, lipid rich necrotic core, thin fibrous caps, neovascularization, and plaque inflammation. A comparison of different non-invasive in vivo imaging of atherosclerosis, specifically ultrasound, computer tomography, and magnetic resonance imaging will be discussed. This article will argue that MRI is best suited for detecting early plaque lesions. Next, the current MR imaging techniques in atherosclerosis will be introduced. Then this article will examine the clinical impact of MRI on atherosclerotic burden based on their vascular location. Lastly, new strategies in MRI imaging of atherosclerosis will be revealed.

Keywords: MRI; Atherosclerotic; Magnetic resonance imaging; Plaques; Clinical applications

Introduction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, commonly caused by thrombotic occlusion of a vulnerable plaque. An estimated 83.6 million American adults (≥1 in 3) have 1 or more types of CVD. Of these, 42.2 million are estimated to be ≥60 years of age. By 2030, 40.8% of the US population is projected to have some form of CVD [1]. CVD, notably atherosclerosis, is a major contributing factor to the total disease burden worldwide. Atherosclerosis is a systemic vascular disease that primarily affects the medium and large vessels and usually manifests by ischemic complications. The diverse clinical presentation of atherosclerosis depends on the vascular beds affected. The severity of the clinical manifestations varies widely. Some patients do not experience any clinical manifestations for years but exhibit evidence of chronic atherosclerotic disease only discovered post mortem [2]. Many others experience sudden clinical events such as ischemic stroke, myocardial infarction, and sudden cardiac death [3-5]. These atherosclerotic lesions that are prone to clinical events have been termed “vulnerable” or “high risk” plaques. These vulnerable plaques are cause by rupture of atherosclerotic plaques ensuing thromboembolic events.

Pathogenesis of Atherosclerosis

Atherosclerosis is characterized by the thickening of the arterial wall resulting in the formations of an atherosclerotic plaque. The etiology of atherosclerosis is influenced by the complex interactions of an individual’s biochemical predisposition and acquired risks factors. The arterial wall thickens to form an atherosclerotic plaque, a chronic process involving cholesterol deposition, inflammation, extracellular-matrix formation and possible thrombosis [6]. The disease remains asymptomatic until the plaques either cause obstruction of blood flow or the plaque matrix give way to plaque rupture triggering vessel occlusions and clinical signs of ischemia. Upon injury to the arterial intima oxidized low-density lipoproteins (LDL)-considered the precursor of atherosclerosis- induce inflammatory response which is believed to play an important role in plaque progression and formation of plaque lipid rich necrotic core and fibrous cap [7,8].

The American Heart Association (AHA) classification grades atherosclerotic lesions based on the lesions type’s composition. Atherosclerosis begins when said oxidized LDL activate expression of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectins, from the endothelial cells. Monocytes migrate from the bloodstream into the wall of the artery and become macrophages. These macrophages deposit fatty materials and accumulate in the inner lining of the arteries over time. Atherosclerotic lesion progress from initial infiltrates of these macrophages and the appearance of foam (Type I) to the lipid-laden smooth muscle cells lesions (Type II) that show gross visualization of fatty streaks characterized by layers of macrophage foam cells and lipid deposition within intimal smooth muscles and heterogeneous droplets of extracellular lipids. Type III lesions are intermediate lesion demonstrating morphological and chemical transitions to advanced lesions [9].

Type IV lesions are the first of the advanced lesions characterized by extracellular lipid accumulation known as the lipid core. The lesion progresses to develop a fibrous cap on top of the lipid core (Type Va), followed by vessel wall calcifications (Type Vb), then fibrosis (Type Vc), and finally Type VI lesions with fissures, hemotema, or thrombosis [10]. Progressively an atherosclerotic lesion can develop new vascular...
connections in the vasa vaeorurn. Hypoxic stresses provoke apoptotic process and proliferations of new blood vessels into the atherosclerotic wall [11]. This process, known as neovascularization, is governed by endothelial cells response to hypoxic conditions in the tunica intima [12]. It has been documented that plaque neovascularization is increased in ruptured atherosclerotic lesions. Studies have indicated that vulnerability of those plaques may be related to plaque composition rather than the degree of luminal narrowing and that cellular and extracellular composition of atherosclerotic plaques are the major determinants of plaque stability [13].

Characterization of the Atherosclerotic Plaque

Current clinical management of atherosclerosis relies on two things: degree of luminal narrowing and patient symptomatology. These two determining factors of the progression of atherosclerosis can be most evidently depicted in the case of carotid artery plaques and corresponding cerebrovascular events. Symptomatic patients with high-grade carotid stenosis are at risk for cerebral infarction and are aggressively treated with carotid endarterectomy [14]. Degree of arterial occlusion, however, is not enough to detect patients at risk for cerebrovascular events. It has been shown that patients with less than 70% carotid stenosis experience and are at risk of stroke [5]. This finding can be attributable to occult atherosclerotic plaque burden and acute arterial occlusion from plaque rupture. Common diagnostic methods, such as angiography, that depend on luminal narrowing cannot accurately measure plaque burden. Arterial walls remodel as a compensatory mechanism to accommodate progressing atherosclerotic plaque and this allows atheromas to increase in size and be displaced outwards before causing any significant stenosis [4]. Arterial occlusion leading to ischemic events can also be caused by plaque rupture with superimposed thrombosis. Plaque morphology affects the risk of plaque disruption, even more than plaque size [3]. Accurate and reliable measurement and characterization of atherosclerotic plaques are, therefore, essential in assessing patients at risk for clinical events.

Determining plaque morphology provides a way of assessing and predicting plaque rupture. Plaque characteristics that contribute to its instability are rupture of the fibrous cap, larger lipid-rich necrotic core, presence of intra-plaque hemorrhage, inflammation of the cap, neovascularization, and irregular superficial calcification of the plaque [3,15-17]. To improve the clinical application of these findings, Gyur-Paquet et al. studied the main components contributing to plaque instability and created a new imaging score for symptomatic plaque assessment. The HULC (hemorrhage, ulceration and lipid core) scoring system balances between sensitivity and specificity of the various factors and is a promising method for a standardized symptomatic plaque assessment [18]. Adventitial vasa vasorum microvessels contribute to inflammation, intra-plaque hemorrhage, and lipid deposition which lead to plaque instability, rupture and subsequent ischemic events [19]. Among the different plaque components, intra-plaque hemorrhage emerged as the most specific factor in predicting plaque instability. Ulceration or rupture of the fibrous cap and lipid-rich necrotic core, on the other hand, showed higher sensitivity [18].

In clinical practice, early identification and characterization of vulnerable atherosclerotic lesions that are likely to lead to clinical events remains a challenge. Consequently, there is a clinical need for the detection of these vulnerable plaques prior to the development of complications. Although the reference standard for radiological detection of severe atherosclerotic vessel wall changes is still confined to arterial luminal diameter, there is growing evidence that offer new imaging techniques which provide information on plaque composition and biological processes associated with plaque progression and destabilization. In due course, these new imaging techniques which aim to detect atherosclerotic lesions in the asymptomatic phase of the disease may potentially reduce atherosclerotic burden in tandem decrease the morbidity and mortality of cardiovascular disease.

Non-invasive In vivo Imaging Modalities

Analysis of the composition of atherosclerotic plaque and accurate measurement of plaque burden will improve patients' embolic risk stratification, prevention, and monitoring of treatment. Patients need a screening tool to help detect early lesions, characterize and locate plaques, monitor atherosclerosis progression or regression, and assess their risk for future cardiovascular outcomes. This is especially true for asymptomatic patients with low-grade stenosis where current clinical standards do not address the possibility of plaque disruption, but rely on the degree of stenosis alone in management decisions. An ideal screening procedure must be accurate, reliable, and have a high sensitivity index in detecting vulnerable atherosclerotic plaques. Furthermore, it must have an excellent cost-benefit ratio, guarantees patient safety, and is readily available. Non-invasive in vivo imaging modalities meet these criteria [20]. Non-invasive procedures have the advantage over the more commonly used angiography procedure in that they do not involve percutaneous access to the vascular system. Currently, the most commonly studied non-invasive in vivo imaging modalities to assess atherosclerotic plaque are ultrasound, computed tomography scan, and magnetic resonance imaging.

Ultrasound uses sound waves to visualize atherosclerotic plaques and to evaluate blood flow. The strengths of transcutaneous ultrasound are it is relatively inexpensive and widely available. It has the capability to demonstrate flow obstruction secondary to stenosis in carotid arteries. B-mode ultrasound imaging is commonly used to directly visualize atherosclerotic plaques, but due to the signal attenuation vessel wall imaging has been limited to shallow vascular beds. B-mode ultrasound can provide a measure of carotid intima-media thickness (IMT) which is a common biomarker used for cardiovascular health. Increase in carotid intima-media thickness is a strong predictor for future vascular events [21]. However, its disadvantages are it is user-dependent, limited by heavily calcified plaque, and restricted to the assessment of superficial vessels.

Although this section discusses non-invasive imaging, it is also important to mention that intra-vascular ultrasound (IVUS) is an invasive sonographic modality that has been used in the assessment of coronary plaque. IVUS permits visualization of coronary arteries via B-mode ultrasound using a small transducer attached to a catheter assess the plaque burden. IVUS demonstrated high predictive accuracies of 87.1% for fibrous, 87.1% for fibro-fatty, 88.3% lipid-rich necrotic core, and 96.5% for dense calcium when compared to plaque specimens from atherectomy. A major challenge with ultrasound techniques is low reproducibility and high measurement variability [6]. Furthermore, IMT does not provide direct information about focal disease or plaque formation and there is a decreased classification accuracy of ultrasound in the presence of calcifications and thrombus. Other modalities, such as MRI demonstrate extensive validations, higher reproducibility, and the ability to monitor the subjects over a period of time which is better suited for plaque quantification and serial analysis.

Another imaging modality, computer tomography (CT), uses ionizing radiation to produce images. Plaque imaging via electron beam CT and multi-detector CT has been used to stratify the risk of future cardiac events by use of the coronary calcium score (CAC). CAC
helps to predict obstructive coronary disease. In a study of 1851 patients who underwent CT angiography and CAC, it showed to have a high negative power (98%) between a negative CAC score (no calcifications) and no obstruction on angiography [6]. Another appealing factor is readily available and less expensive than magnetic resonance imaging [22].

It is a less frequently used imaging technique in detecting atherosclerotic plaque because of its many disadvantages. CT generates poor soft tissue images, produces artifacts in calcified plaques, has subpar delineation of plaque components, and exposes patients to ionizing radiation that increases their risk for cancer. This modality is not effective for detecting other components of vulnerable plaques: thin-cap fibroatheromas and presence of inflammatory cells [23]. Non-calcified coronary plaques have been detected and classified by CTA but supported by histological validation is lacking [24-27]. Compared to ultrasound and MRI, radiation exposure from CT is a concern for screening and serial imaging. Motion artifacts are also a limitation for CT imaging, particularly in studies on coronary vessels. Conditions like arrhythmias and high cardiac rates are a challenge even with faster 64 slice CT scanners. Blooming artifacts from extensive calcification can lead to over-estimation of lesion severity [28].

MRI has emerged as a novel modality for detecting and characterizing atherosclerotic plaques. Research and clinical applications of MRI characterization of atherosclerosis has established the diagnostic value of MRI in assessment of plaque burden. A patient is placed on a strong magnetic field and an MRI image is produced from the emitted radiofrequency signals of protons. It has outstanding soft tissue contrast and delineation of plaque components. Plaque characterization is reproducible and has been validated in numerous studies. MRI imaging has also been employed in assessing large vessels such as the aorta [29] as well as smaller ones such as peripheral arteries [30]. It does not expose patients to radiation, has satisfactory spatial resolution, and can be used for serial imaging. Since it takes a longer time to produce an image, respiratory and cardiac movements interfere with the quality of images. Thus, it has limited application in coronary arteries [31]. There is also need for a standardized protocol to be established for the analysis of plaque characteristics. In addition, not all patients are eligible for an MRI scan, particularly those who have pacemakers and who are claustrophobic. Table 1 compares the imaging capacities of ultrasound, CT, and MRI and their respective imaging capacities. MRI appears to be the leading non-invasive in vivo imaging modalities to characterize atherosclerotic plaques.

### Different MRI Imaging Modalities of Atherosclerosis

MRI imaging of atherosclerotic plaques is based on the signal intensity and morphology of the plaque on multiple contrast weightings. The signal intensity of these plaques varies according to the proton density (PD) and relaxation time (T1 and T2). The multi-contrast images, both bright blood (i.e. time-of-flight) and black blood (i.e. T1W, T2W, PDW with blood-flow suppression) can be used complimentary for visualization of various plaque components such as fibrous tissue, hemorrhage, and dense calcifications. Bright-blood imaging techniques suppress the signal from the surrounding tissues and enhance luminal signals. Therefore, it is primarily applied for evaluation of luminal stenosis. Whereas black-blood imaging attenuates luminal signals for better visualization of vessel wall and provides better outline of the luminal surface and identification characteristics such as intraplaque hemorrhage or fibrous cap rupture. MRI offers versatility to examine different components of atherosclerotic plaques through diffusion, contrast uptake, dynamic contrast permeability, and magnetization transfer. This section aims to provide an overview of the various MRI modalities currently used in the study of atherosclerotic plaques.

### Magnetic Resonance Angiography with Time-of-Flight Sequence

Magnetic resonance angiography (MRA) with time-of-flight sequences (TOF) provides the capability to measure luminal narrowing. The lumen appears bright and blood flow obstructions can be readily apparent. TOF can aid in assessment of fibrous cap thickness and integrity because it can delineate the lumen shape and internal borders of the plaque. However, this technique cannot separate plaque components or measure the amount of plaque. Black-blood inversion technique has been developed to address this and aid in arterial wall thickness and plaque analysis. Gupta et al. demonstrated that assessment of embolic risk could be made more available to most centers using 3D TOF MRA and standard neck coils. 3D TOF MRA was used to assess intra-plaque hemorrhage (IPH) in this study. Figure 1 shows MRI of intraplaque hemorrhage in T1W, PDW, and T2W imaging and portrays the various vulnerable plaque components. Intraplaque high-intensity signal (IHIS), defined as higher than 50% signal intensity than skeletal muscle, was employed as a surrogate marker for IPH. Patients were scanned using standard quadrature neck array coils, instead of specialized surface carotid coils. Their findings showed that patients with 70 to 99% carotid stenosis and IHIS are 14% more likely to have had prior ischemic event than those who have high-grade stenosis and no IHIS. Having shown that patients with IHIS and carotid stenosis are associated with cerebrovascular events, the more widely accessible 3D TOF MRA using standard neck coils has the potential to be used to evaluate for future cerebrovascular risk [32].

For other plaque characteristics that indicate instability, it appears that TOF offers poor visualization of these plaque components. In a study by Etesami et al., TOF MRA missed a third of plaque ulcers that were detected using contrast-enhanced magnetic resonance angiography (CE-MRA). TOF ulcer detection are easily affected by ulcer position, distance to stenosis, and neck-to-depth ratio [33]. Plaque ulcers in TOF images can also be mistaken as IPH. Blood turbulence within the plaque crater has signal intensity similar to IPH and may result to false-positives [34].

Another disadvantage of unenhanced TOF is overestimation of carotid stenosis in areas of turbulent blood flow [35]. TOF is also limited by motion and flow-associated artifacts. Patient movement results to blurring between tissue interfaces. An example of flow-related artifact is decreased clarity in areas of luminal narrowing [36].

### Table 1: Comparison of plaque imaging modalities.

<table>
<thead>
<tr>
<th>Modality</th>
<th>US</th>
<th>CT</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spatial Resolution (μm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penetration Depth (nm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid Pool</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinous Cap</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraplaque Hemorrhage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neovasculature</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; NA, not applicable [63,70].
Contrast-Enhanced MRI (CE-MRI)

One limitation of unenhanced MRI is the contrast-to-noise ratio (CNR) of the vessel wall that leads to lower resolution of vessel wall and plaque images. Contrast agents are used to improve CNR and provide better visualization of the vessel wall and plaque. A contrast agent, like gadolinium, accumulates in atherosclerotic plaques leading to increase in signal intensity. Zhang et al. demonstrated that contrast-enhanced images correlate more closely to the histological specimen measurements of the wall compared to non-contrast images [37]. Barkhausen et al. also showed that CE-MRI could be used to visualize plaques not seen unenhanced images. It can also detect early-staged atherosclerosis in vessels where luminal narrowing is not yet seen. CE-MRI, thus, leads to more accurate wall measurements and enhances imaging of atherosclerotic plaques [38].

These contrast agents are indirectly detected by their effect on the surrounding water protons. Application of the receptor-induced magnetization enhancement (RIME) phenomenon, where the contrast agent binds to the macromolecule of the tissue of interest significantly slowing down the molecular rotation of the contrast agent, such as gadolinium, permits for increased relaxation and thus increased tissue contrast enhancement [39]. T1-shortening MR contrasts are predominately based on gadolinium. The molecular properties of gadolinium provide a spin relaxation time that is slow enough to allow for significant interaction with adjacent water protons. It has been shown that gadolinium-based contrast agents have a stronger effect on the shortening of T1 than T2 relaxation time [40]. This increase in signal intensity on T1-weighted images is termed positive contrast effect. While T2 relaxation time can also demonstrate considerable shortening, it has only observed in high concentrations.

Contrast-enhanced MRI allows for differentiation of plaque components which helps identify patients at risk for ischemic events. CE-MRI can enhance fibrous caps, allow their quantitative measurements, and distinguish intact from ruptured caps [38,41,42]. Quantitative measurement of fibrous caps is important because thin fibrous caps are more prone to rupture and this disruption of caps leads to embolism. The underlying collagen and lipid core of the ruptured plaque may also become exposed to blood components triggering the process towards thrombosis. Lipid-rich necrotic core (LRNC), can be assessed accurately by CE-MRI where it appears darker with contrast. The absence of vessels and matrix in this area of plaque results in minimal or no enhancement upon contrast administration. This difference in enhancement can be used to delineate LRNC and measure its size. Using CE-MRI T1-weighted imaging, the short-term regression or progression of LRNC in subclinical carotid atherosclerosis has been studied. Results showed that the presence of IPH appeared to be major factors in LRNC progression or regression and not statin therapy [43].

Gadolinium contrast can also be an indicator for inflammation and neovascularization. Papini et al. has been able to compare in vivo MRI images with cellular infiltrate on histology. Increase in contrast enhancement showed an increase in inflammation in histological specimens [44]. Both fibrous tissue and neovascularization have been reported to have higher signal enhancement than other plaque components, whereas the lipid-rich necrotic core tends to have a slower uptake and lower enhancement. Contrast-enhanced standard MRA technique has been shown to be highly sensitive for identifying IPH. A highly T1-weighted sequence with no increase in scan time yields results similar to specialized IPH techniques in regards to IPH detection [34].

T2-shortening MR contrast agents are predominantly based on iron oxide particles induce stronger T2 shortening compared to T1 relaxation times which results in a negative contrast effect which is detected as signal voids. Ultra-small super-paramagnetic iron oxide nanoparticles (USPIO) act as contrast media that demonstrate inflammation via macrophage imaging. USPIO are nanoparticles with an iron oxide core stabilized by a polymer coating that were initially used for imaging of the reticuloendothelial system, tumors, and inflammatory diseases of the central nervous system. Their application has expanded to include the imaging of atherosclerotic plaque [45]. Endothelial dysfunction during the atherosclerotic process triggers inflammation and lipid accumulation in the vessel wall. USPIO, due to their small size and water-solubility, extravasate through this inflamed and permeable endothelium. They accumulate in atherosclerotic plaques and, like lipid particles, are also taken up by macrophages. When macrophages internalize the iron particles, these particles generate their own magnetic fields that offset signals on T2-weighted images. The result is a signal loss that correlates with the amount of macrophage uptake and inflammation in the tissue [46].

A limitation of this technique is that signal diminution may also be caused by other factors such as calcified tissue and respiratory motion [46]. Ruptured atherosclerotic arteries also showed an increase accumulation of USPIO in rabbits compared to non-disrupted arteries [47]. In addition to ruptured arteries, Kooi et al. demonstrated that USPIOs are also predominant in vulnerable plaques in humans [48].

Macrophages consume USPIO via a non-specific receptor-mediated endocytosis. A high amount of contrast agent was administered to animal models to be able to have enough particles internalized by macrophages. To decrease the needed dose, studies have been done to increase the affinity of these cells to USPIO. Since macrophages in atherosclerotic plaque express mannose receptors, this has been studied as a way of increasing uptake and decreasing the dose. A study comparing four types of superparamagnetic iron oxides showed that mannan-coated SPIO and USPIO were more superior to unbound SPIO and USPIO in atherosclerosis imaging [49]. Tsuchiya et al. demonstrated that mannan-dextran coated USPIO is also more easily taken up by macrophages than dextran-USPIO [50].

MR molecular imaging with target specific molecular probes
demonstrates the potential for non-invasive in vivo visualization of biological processes on the molecular and cellular level. There are several different classes of target-specific MR contrast agents available for molecular imaging. Molecular MR contrast agents, which enhance specific molecules (eg, elastin, fibrin, VCAM-1) or cells (eg, macrophages), allow visualization of pathologic processes on a molecular level with high spatial resolution; molecular MR imaging of atherosclerosis has the potential to improve early detection, guidance of treatment, and monitoring of treatment response. A fibrin-specific peptide conjugated to four gadolinium tetrazacyclododecane tetracetic acid (FTCA, EPIX pharmaceuticals, Lexington, MA) successfully demonstrated intraplaque and endothelial fibrin imaging in vivo with molecular MRI after FTCA administration demonstrated a significant increase (P<0.05) in contrast agent uptake [51].

**Dynamic Contrast-Enhanced MRI**

Dynamic-contrast-enhanced (DCE) MRI is traditionally used in studying tumor microvasculature and angiogenesis but it was also served as a useful tool for quantification of the extent of plaque neovascularization [44]. DCE MRI can directly measure the effect of increased blood flow in the adventitia of newly formed vessels. In atherosclerotic plaque imaging, DCE-MRI is used to quantify adventitial vasorum neovascularization and its permeability. This is done through determining kinetic parameters of contrast uptake such as measuring the transfer constant (vessel surface area and permeability) and blood flow [19]. The change in signal intensity is measured over time using T1W dynamic MR with high temporal resolution.

In DCE-MRI bright blood imaging utilizes the hyperintense signal emitted by flowing blood making it an ideal technique for assessing plaque microvessel density. In black blood imaging, blood flow and lumen signals are suppressed allowing for a more accurate vessel wall measurement and differentiation. Chen et al. was also able to use DCE-MRI to study neovascularization and inflammation changes of early plaque lesions over time [52].

Calcagno et al. developed a new method to increase the sensitivity of DCE MRI in measuring neovascularization in atherosclerotic plaques. Parameters important in evaluating neovessels, vessel wall uptake and arterial input function, were evaluated using a simultaneous high and low spatial temporal resolution (SHILO) imaging technique. SHILO was validated against its standard counterpart, 2D spoiled gradient recalled echo (SPGR) acquisition, and results in both techniques were validated against its standard counterpart, 2D spoiled gradient recalled echo (SPGR) acquisition, and results in both techniques were compared to a marker of inflammation, neovessel count, obtained from immunohistochemistry. Both PET and DCE-MRI were found to positively correlate with the neovessel count. Thus, these two imaging modalities could be useful for future studies in quantifying inflammation and detecting unstable atherosclerotic plaques [55].

**Positron Emission Tomography-MRI**

At the forefront of non-invasive in vivo imaging of atherosclerosis is the use of positron emission tomography (PET) imaging in combination with MRI. PET assesses the metabolic activity of tissues and has been indispensable in the field of oncology. Its use has expanded to include investigation of atherosclerotic plaques. PET commonly uses 18-Fluorodeoxyglucose (FDG) as a tracer. FDG is a glucose analogue with a radioactive isotope, fluorine-18, at carbon 2. When inflammation increases the metabolism of glucose in tissues, FDG is taken up in cells the same way as glucose. Unlike its counterpart, FDG cannot be degraded and transported out of the cell. PET detects FDG accumulation in cells and measures it as SUV, standardized uptake value. SUV is increased in atherosclerotic plaques with unstable morphology and in sites of inflammation. These two are established factors that contribute to plaque rupture and subsequent acute thrombosis. Thus, PET imaging can quantify inflammation, tissue metabolism of glucose, and help in risk stratification of patients.

PET has a low spatial resolution that makes it susceptible to partial volume errors. To address this, it is usually co-registered with CT or MRI. PET will provide the information on metabolic activity and inflammation, while CT or MRI will allow for better visualization of anatomic structures and localization. Although promising, this system has several disadvantages. When patients are scanned in separate machines, lining up the anatomy in fusion programs can be burdensome. Putting the patient in the same position when scanning can also be challenging. In addition, PET makes use of isotopes that exposes patients to radiation. If coupled with CT, this will subject patients to additional exposure to radiation putting them at risk for cancer.

A combined PET-MRI machine for the imaging of atherosclerosis may prove to be a better alternative. MRI does not expose patients to radiation and has a more superior soft tissue contrast than CT. A study by Ripa et al. compared the performance of PET-CT vs PET-MRI in carotid arteries. Both were done to six HIV patients in less than an hour. SUV results between the two systems were found to be similar. PET-MR, however, was found to be better in differentiating the vessel wall. In addition, it is interesting to note that the study was done on patients without significant atherosclerotic plaques. Although certainly a limitation, this shows that the use of PET-MRI could be feasible in this type of patients who are in the early stages of atherosclerosis [54].

Taking a step further, Calcagno et al. studied the potential of PET and diffused contrast enhanced imaging (DCE-MRI) in assessing atherosclerotic plaque inflammation by detecting the presence of neovessels. Inflammation of atherosclerotic plaques has been linked to their subsequent neovascularization. Black blood sequence for DCE–MRI was utilized in the study to increase delineation of plaque characteristics. The results of the two imaging modalities were compared to a marker of inflammation, neovessel count, obtained from immunohistochemistry. Both PET and DCE-MRI were found to positively correlate with the neovessel count. Thus, these two imaging modalities could be useful for future studies in quantifying inflammation and detecting unstable atherosclerotic plaques [55].

**Clinical Applications of MR imaging based on Vascular Territories**

The risk of complications of atherosclerosis affects certain circulatory regions and yields distinct clinical manifestations depending on the particular circulatory bed affected. Atherosclerosis of the blood supply to the central nervous system (CNS), chiefly the carotid arteries, frequently incite ischemic stroke or transient cerebral ischemia. In the coronary arteries, myocardial infarction is commonly attributed to atherosclerosis. Mesenteric ischemia can be caused by atherosclerosis of the splanchnic circulation. Atherosclerosis in the peripheral arteries can cause claudications and jeopardize limb viability. This section will describe the current developments in MR imaging of atherosclerotic plaques and its clinical application to the most susceptible circulatory regions for thrombo-embolic events; carotids, aorta, coronary arteries, and peripheral arteries.

**Carotid Arteries**

Some of the most significant developments in MRI of atherosclerosis
in recent years pertain to the baseline MRI characteristics of carotid atherosclerosis with clinically relevant outcomes. Features of carotid arteries such as superficial location and relative immobility make these vessels better suited for atherosclerotic plaque MR imaging than do other vessels such as the aorta or coronary arteries. Figure 2 show MR imaging techniques to assess plaque burden in carotid arteries. The measurements of carotid IMT-a strong predictor of future vascular events- by unenhanced T1-, T2- and PD carotid MRI has been found comparable to that of carotid B-mode ultrasound [56].

Using MRI, studies show that type VI lesions with evidence of vulnerable plaque features, like IPH or cap rupture, have commonly been identified in carotid arteries with minimal to moderate stenosis [57]. An association between carotid IPH and cerebral ischemia was originally established by comparing in vivo preoperative imaging of atherosclerotic lesions with corresponding histological findings of carotid endarterectomy (CEA) specimens [58]. A strong association is reported between fibrous cap thinning/rupture, as determined by MRI TOF vessel wall imaging, and recent history of cerebrovascular events. T2W imaging of human carotid atherosclerotic plaque specimens has accurately detected advanced lesions type Vb fibrocalcific plaques [59]. Multi-contrast high resolution MRI can reliably identify intermediate to advanced atherosclerotic lesions and distinguish advanced lesions from early and intermediate in accordance with AHA classification [41].

There is abundant evidence that supports that MR imaging can display plaque vulnerability features i.e. IPH and fibrous cap disruption, in vivo in both asymptomatic and symptomatic cohorts of carotid stenosis. In a prospective study on patients initially asymptomatic with 50% to 79% carotid stenosis, arteries with thinned or ruptured fibrous caps, intraplaque hemorrhage, larger maximum percentage lipid-rich necrotic cores, and larger maximum wall thickness by MRI were associated with the occurrence of subsequent cerebrovascular events [60]. Multivariate cox regression analysis demonstrated a significant association between baseline MRI identification of the following plaque characteristics and subsequent symptoms during follow-up: presence of a thin or ruptured fibrous cap (hazard ratio, 17.0; P< or =0.001), intraplaque hemorrhage (hazard ratio, 5.2; P=0.005), larger mean intraplaque hemorrhage area (hazard ratio for 10 mm2 increase, 2.6; P=0.006), larger maximum percentage lipid-rich necrotic core (hazard ratio for 10% increase, 1.6; P=0.004), and larger maximum wall thickness (hazard ratio for a 1-mm increase, 1.6; P=0.008) [61]. Singh et al. conducted a cohort on asymptomatic moderate carotid stenosis showed that IPH - detected by rapid three-dimensional T1-weighted fat suppressed gradient-echo sequence - was associated with an increase risk for ipsilateral cerebrovascular events. Of the 91 initially asymptomatic males with 50-70% stenosis, all six of the cerebrovascular events occurred in arteries with a baseline IPH (hazard ratio, 3.59; 95% confidence interval: 2.48, 4.71; P < .001) and MR-depicted IPH negatively predicted outcomes (negative predictive value = 100%) [60]. Among the 64 symptomatic patients with 30-60% stenosis followed for a mean period of 28 months, thirty nine (61%) showed baseline IPH on MRI. Of those with baseline MRI-depicted IPH, 13 developed ipsilateral ischemic events, with only one reported TIA among those with no baseline IPH (hazard ratio, 9.8; P=0.03) [62]. The presence of hyperintense signals on TOF, representing IPH, in a study of 112 patients for carotid artery stenting (CAS) showed a significantly higher likelihood of periprocedural symptoms (18.4% vs 1.4%, p=0.0003) [63]. Ota et al. used 3T MRI to show intraplaque hemorrhage and larger percentage of lipid-rich necrotic core are independently associated with thin or ruptured fibrous caps in patients with more than 50% carotid stenosis. This multivariate ordinal regression analysis demonstrated larger percentage of LRNC (odds ratio for 10% increase, 1.49; P=0.02) and presence of hemorrhage (odds ratio, 5.91; P<0.001) were independently associated with a worse (intact thin or ruptured) stage of fibrous cap status. For artery-based multivariate analysis, a larger maximum percentage of LRNC and presence of hemorrhage independently associated with worse fibrous cap status (P<0.001, for both) [64]. Hence, different MRI weightings can be used to determine the location, morphology, and composition of advanced plaque lesions.

High intensity signals observed in carotids plaque using inversion recovery-based 3D T1W imaging are associated with recent ischemic cerebrovascular events [65-67]. Carotid MR imaging has documented IPH using methemoglobin as an endogenous contrast agent resulting in a shortening of the T1 relaxation time and a hyperintense signal on T1W images. This technique, also termed as magnetization-prepared rapid acquisition with gradient echo (MPRAGE) or magnetic resonance direct thrombus imaging (MRDITI), can examine the components of complex AHA type VI plaques such as luminal surface defects, hemorrhage, thrombus, or calcified nodules [10,68,69]. MRDITI has been used to visualize intraplaque hemorrhage in patients with cerebral ischemia. The prevalence of AHA type V1 carotid lesions using MRDITI in patients with varying degrees of carotid stenosis has been reported. The prevalence of high signal was significantly greater in the asymptomatic patients’ ipsilateral vessels compared with the contralateral side (60% versus 36%, chi2 P<0.001), particularly for vessels of only moderate stenosis. The sensitivity and specificity of

---

**Figure 2:**


---

[Image 333x108 to 540x246]

[Image 333x266 to 548x405]
MRDTI for detecting complicated plaques was 84%, with a positive predictive value (PPV) of 93%, and a negative predictive value (NPV) of 70%. There is also a significant negative correlation between the minimum luminal area and complicated AHA type VI. High degree stenosis (80-90% luminal narrowing) had lesions with a LRNC was detected in 92% of all patients. The LRNC increased considerably with the higher degree of stenosis [69].

Carotid MRI studies demonstrate high level of reproducibility in assessment of plaque burden. Reproducibility of measurements on multiple scanner platforms has been established [70]. Plaque component identification has been widely validated and plaque composition has been accurately identified [38,41,71]. Fibrous cap, LRNC, hemorrhage, and thrombus have been identified on multi-contrast MRI [43,61,69,72-74]. The accuracy and reproducibility of LRNC measurements via MRI show high sensitivity (85%) and specificity (92%), which has been utilize in the monitoring the plaque progression and regression [75-79].

Prospective MRI studies have also examined the role of components the atherosclerotic lesions in plaque progression. Takaya et al. showed that IPH, detected by HR MRI, is associated with greater plaque progression in both necrotic core and plaque volume [80]. IPH is shown to be an indication of accelerated plaque growth and luminal obstruction [81]. Sluimer et al., proposed that the destruction of the integrity of microvessel endothelium likely leads to intraplaque hemorrhage and plaques at increased risk for rupture [82]. Neoangiogenesis in atherosclerotic plaques has been implicated in the etiology of IPH, which when combined with LRNC, thin fibrous cap, and inflammation, can possibly serve as a good marker of vulnerable plaques. In recent years, plaque neoangiogenesis has become a target for asymptomatic vulnerable lesions and MRI is a non-invasive tool to further examine the underlying mechanisms. In terms of plaque regression in monitoring response to anti-atherosclerotic therapies, Corti et al. found a 15% reduction in the carotid wall area after 12 months of simvastatin treatment with no change is normal wall measurements [77]. Zhao et al. conducted a prospective assessment of MR carotid plaque composition during lipid lowering therapy and noted that after 3 years of lipid therapy, the 33 subjects with measurable LRNC at baseline had a significant reduction in plaque lipid content. Intensive lipid therapy significantly depletes carotid plaque lipid. Statistically significant plaque lipid depletion is observed after 1 year of treatment and continues in the second year, and precedes plaque regression [83].

Aorta and Coronary Vessels

There are numerous studies that assess and atherosclerotic burden in the thoracic and abdominal aorta. Thoracic aortic MR vessel wall imaging was found to be in good agreement with trans-esophageal echocardiography (TEE) in respect to plaque composition and thickness [29]. Figure 3 shows MR T1 and T2 images of atherosclerotic descending aorta. Although plaque extent in the aorta -both thoracic and abdominal- correlated with the severity of CAD, only thoracic plaques were independently associated with CAD [84].

In previous years, several reproducibility of studies of aortic wall measurements using multi-contrast MRI showed good inter-reader, intra-reader, and interscan reproducibility [85]. Since then, Calcagno et al showed good interscan and excellent intra- and interobserver reproducibility in an animal model of atherosclerosis using black-blood DCE MRI [86]. The application of DCE MRI monitoring high risk patients and in longitudinal clinical drug trials is currently being evaluated. Similar to carotid MR imaging, aortic vessel wall MR imaging studies directly visualize and quantify regression and progression of aortic atherosclerosis in response to different anti-atherosclerotic therapies.

A major challenge in MRI imaging of thoracic aorta is achieving sufficient sensitivity for submillimetre imaging and elimination of artifacts due to respiratory motion and pulsatile changes produced by blood flow. Such challenges have been addressed by technical
improvements in magnetic field strength, dedicated sequences (such as double-inversion preparation pulses to suppress the signal of flowing blood), and navigation techniques to correct for respiratory motion [31].

As mentioned previously, MR imaging of coronary vessels is technically more challenging than other vascular beds. Coronary vessel wall imaging requires high resolution and high SNR due to the size of the vessel wall. Coronary imaging is further complicated by the need for cardiac and navigator gating. Respiratory compensation can be breath hold or free breathing with navigator echo monitoring the diaphragmatic motion. Recent improvements on navigator technology include ultrafast motion tracking, motion-adapted gating strategies, and the use of multiple navigators. The intrinsic motion of the coronary arteries during the cardiac cycle requires electrocardiographic synchronization of data acquisition [87].

Several studies support the coronary vessel MR imaging as a useful tool in detection of early atherosclerotic lesions in the coronary arteries. In a large asymptomatic multiethnic population, vessel wall MRI detected significant number of individuals with positive coronary remodeling with no history of CAD [88,89]. T2-weight black-blood coronary vessel wall MRI has been successful in detection and quantification of increased coronary vessel wall thickness and positive remodeling in patient with CAD confirmed by X-ray angiography. Coronary arterial plaques were first demonstrated in a porcine model using 2D T2W and PDW imaging sequences and validated with histopathology correlation [90].

Fayad et al. first demonstrated the feasibility of in vivo coronary plaque imaging using a spin echo black blood technique in humans [29]. Improvements in this technique allowed for free breathing through combining real-time navigator for respiratory gating and real-time slice-position correction [91]. High inter-study reproducibility has been established for serial evaluations of coronary vessel wall imaging and CAD [92]. Increased coronary wall thickness has been detected in patients with early CAD using MRI with isotropic resolution [93].

Currently, coronary MR angiography (CMRA) is a promising non-invasive alternative for visualizing of coronary arteries. 3D steady-state free precession (SSFP) whole-heart CMRA is an unenhanced technique that permits visualization of all major coronary arteries with a single, axial 3D acquisition. Yoon et al demonstrated that CMRA is useful in predicting the risk of cardiac events in patients suspected to have CAD. Of the 207 patients with suspected coronary artery disease who underwent non-contrast-enhanced free-breathing whole-heart CMRA, there were 10 cardiac events- five of which were severe, observed in 84 patients with significant stenosis. In the 123 patients without significant stenosis, only 1 cardiac event with no severe event was observed. A significant difference in event-free survival between the 2 groups for severe events (annual event rate, 3.9% and 0%, respectively; log-rank test, p = 0.003) was seen as well as for all cardiac events (6.3% and 0.3%; p < 0.001). Cox regression analysis significant stenosis on CMRA was associated with a >20-fold hazard increase for all cardiac events (hazard ratio: 20.78; 95% confidence interval: 2.65 to 162.70; p = 0.001) [94].

Delayed-enhancement imaging of the coronary artery wall is another technique used which allows for direct assessment of contrast agents uptake in the vessel wall. In vivo, delayed enhancement showed nonspecific uptake in plaques in both patients with chronic angina and in those with acute coronary syndrome (ACS). Ibrahim et al. studied atherosclerotic plaque enhancement after acute myocardial infarction displayed coronary vessel wall contrast agent uptake is significantly increased early after myocardial infarction compared to those observed after 3 month follow up images [95]. This decrease in contrast uptake on follow up suggests uptake in patients ACS was more transient and more likely to be attributed to inflammation.

Due to the limited data on coronary vessel MR imaging, there is a need for more prospective data on these modalities to investigate the clinical role of these techniques for better diagnosis and characterization of CAD.

Peripheral Arteries

There have been some developments in MR imaging on disease of peripheral arteries. Angiography has been widely used for assessment of peripheral artery disease (PAD) caused by atherosclerosis [96]. Vessel areas and calcifications measured on high resolution TOA MRA were found to be in good agreement with IVUS measurement [97]. Measurement of plaque volume of the femoral artery has demonstrated interobserver, intraobserver, and test-retest reproducibility on black blood imaging [98]. Vessel wall measurement of femoral arteries is comparable in both 3D T2-weighted and 2D T1-weighted fast spin echo [99]. Due to poor spatial coverage, 2D imaging techniques for evaluation of PAD in vivo alternative MRI modalities have been studied to improve plaque detection and characterization lesions in the peripheral arteries. Hayashi et al showed that diffusion prepared dark blood 3D steady state free precession (3D-DP-SSFP) sequence indicated a higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR) compared to 2D-TSE technique. Figure 4 displays dark blood MRI protocol for femoral plaque imaging. This study showed excellent inter-operator reproducibility for 3D plaque burden [100]. In addition, Lui et al. showed improved arterial wall delineation in susceptibility weighted phase imaging of peripheral arterial walls [101].

Cross-sectional MRI analysis have shown to be a useful prognostic tool in monitoring plaque remodeling and restenosis. MR imaging has been applied in the development of restenosis of lower extremity bypass grafts by means of providing serial imaging of subjects to document progression of disease [102]. Efficacy of percutaneous transluminal angioplasty and its combination with endovascular brachtherapy, multicontrast double inversion recovery fast spin echo (DIR-FSE) was used to detect changes in vascular remodeling [103].

CE-MRA of the renal and aorto-iliac-femoral arteries has shown to detection significant steno-occlusive disease using different gadolinium-based contrast agents. CE-MRA with gadobenate dimeglumine was more specific (92.4% vs. 80.5%, p<0.0001) and accurate (83.6% vs. 77.1%, p=0.022) than CE-MRA with gadofosveset in the detection of significant renal artery stenosis. The average sensitivity was higher for gadofosveset (74.4% vs. 67.3%, p=0.011) in peripheral vessels although gadobenate dimeglumine was more specific (93.0% vs. 88.2%, p<0.0001) with no difference in accuracy (86.6% vs. 86.3%, p=0.66). PPV’s were higher (p<0.0001) for gadobenate dimeglumine in both vascular territories. Pre- to post-test shifts in the probability of detecting significant disease were greater after gadobenate dimeglumine. Adverse events in the renal and peripheral studies were reported by 9.2% and 7.7% of patients after gadobenate dimeglumine compared with 30.3% and 22.1% of patients after gadofosveset [104].

In the largest comparative study to date, Hansmann et al. tested the diagnostic accuracy of time-resolved MRA of the calves compared to continuous-table movement MRA in symptomatic patients with lower extremity peripheral artery disease using digital subtraction angiography (DSA) as a reference standard. This study established
that time-resolved MRA increases diagnostic accuracy of calf station. Median image quality of time-resolved MRA was rated excellent compared to continuous-table-movement MRA. Inter-reader agreement was excellent (κ=0.80-0.84). The diagnostic accuracies (continuous-table-movement MRA/time-resolved MRA) combined for the readers were obtained for the tibioperoneal trunk (84%/93%),

**Figure 4:** Dark blood MRI protocol for femoral plaque imaging. A) 2D black blood turbo spine echo (TSE) sequence using different contrast weightings to evaluate plaque composition in femoral artery. B) 3D Multi planar reformatting (MPR) of femoral artery with plaque indicated by orange arrow. C) MPR Diffusion SSFP. D) MRP SPACE.
anterior tibial (69%/87%), posterior tibial (85%/91%), and peroneal (67%/81%) arteries. The advantages of time-resolved MRA include reduced venous contamination, improved arterial phase of contrast enhancement, and more precise delineation of vascular anatomy in comparison to continuous-table-movement MRA. This evidence supports the addition of time-resolved MRA to continuous-table MRA of the calf station as robust diagnostic approach for advanced PAD [105].

Future Perspectives of MRI imaging of Atherosclerosis

For asymptomatic patients with low-grade carotid artery stenosis, screening with a non-invasive in vivo imaging method like MRI can be a useful tool in detecting vulnerable atherosclerotic plaques. Plaque compositions that indicate instability have been identified. However, large clinical trials are needed to assess the direct clinical correlation of these plaque characteristics to cardiovascular and neurologic events. Selection criteria that are reliable and reproducible for identifying plaques at risk of causing an ischemic event are crucial in bringing this method of imaging to the clinical setting.

Temporal stability of atherosclerotic plaques is another aspect of atherosclerotic plaque analysis that requires further study. Clinical studies need longer follow-up times to determine the natural course of these plaques. There is a need for more definite clinical correlation and a better understand of the temporal evolution of vulnerable plaques which could improve risk stratification and management algorithms-including clinical trials on lipid lowering drugs, for those identified with early lesions of atherosclerosis. In the largest prospective study to date of patients with moderate to severe symptomatic carotid disease, Akram et al. determined the predictive power of intraplaque hemorrhage (IPH) for recurrent stroke with a follow-up of 9 years. 179 patients with previous cerebral ischemic events and more than 50% carotid stenosis underwent brain and neck MRI imaging. 1.5 T scanners and standard quadrature neck array coils were used in the study. Intraplaque hemorrhage was found to strongly and independently predict secondary ipsilateral ischemic events in this subset of patients. Hosseini et al. also performed a meta-analysis of studies involving MRI imaging of patients with carotid stenosis. IPH was determined to be significantly associated with new and recurrent cerebral ischemic events for symptomatic patients. This shows that IPH is a possible biomarker for thromboembolic risk for patients who had previous ischemic events. For patients with asymptomatic carotid stenosis, however, it was found that available studies are limited with a small sample size and their allotted time for follow-up are inadequate to make any conclusion regarding the predictive value of IPH [106].

MRI imaging of atherosclerosis has also been studied in coronary arteries and other vessels. In the Multi-Ethnic Study of Atherosclerosis (MESA), compensatory enlargement of the arterial wall seen in early atherosclerosis was detected in patients without any history of coronary artery disease [89]. Coronary artery MRI imaging can present a major challenge because of the tortuosity of coronary arteries, cardiac and respiratory movement, and low spatial resolution. MRI imaging protocols that combine speed and resolution are being developed to overcome these inherent limitations of coronary imaging.

Since adequate non-invasive imaging of vulnerable atherosclerotic plaque in coronary arteries is still a work in progress, Wang et al. determined in a study that the carotid artery could be a window to the coronary arteries. Based on the premise that atherosclerosis is a systemic inflammatory disease of vessels in general, vulnerable carotid artery plaques may be used as a surrogate marker to identify patients at risk for acute coronary syndromes (ACS). In this study, ruptured carotid plaques are more common in patients with ACS compared to those with stable angina. Thus, ruptured carotid plaques may be used as an indication that patients are at risk for ACS [107]. More recently, carotid plaque vulnerability can also be useful in predicting future coronary events as well as cerebrovascular. Noguchi et al determined whether carotid high-intensity plaques (HIP) visualized by MPRAGE could be a predictor for coronary events. In 217 clinically stable CAD patients, the signal intensity of carotid plaques detected by MPRAGE and IMT measured by ultrasonography were examined and followed up for as long as 72 months. A carotid HIP was defined as a signal >200% that of the adjacent muscle. They found a significant association between the presence of HIP and cardiac events compared to non-HIP (log-rank P<0.0001). Multivariate Cox regression identified the presence of HIP as the strongest independent predictor of cardiac events (hazard ratio: 3.15; 95% confidence interval: 1.93 to 5.58, p<0.0001) compared with IMT (hazard ratio: 1.62, 95% confidence interval: 0.97 to 2.44, p=0.055) and other coronary risk factors [108]. Coronary imaging is a field of potential great impact for MRI imaging of atherosclerosis.

Currently, MRI imaging of atherosclerosis is limited to the field of research. For it to be applicable widely in a clinical setting, a standardized MRI protocol that maximizes visualization of the plaque and its components also needs to be established. Cost-effectiveness of the imaging technique is a concern. Training staff to employ the new protocol and analyze the images, obtaining dedicated coils, and the cost of MRI itself can be prohibitive for this imaging method to be a screening tool. Nevertheless, it will still be a more acceptable step compared to the invasive angiography procedures for asymptomatic patients.

Conclusion

Early assessment of atherosclerotic lesions is an important diagnostic goal in terms of decreasing the CAD burden. This review of MRI techniques of atherosclerosis provides an overview of the current MRI techniques and their clinical relevance. Magnetic resonance imaging is a well-established and reproducible technique that provides comprehensive information on the morphology, composition, and biochemical markers of atherosclerotic plaques and present high spatial resolution and good soft tissue contrast. Intraplaque hemorrhage and lipid rich necrotic core are considered the best indicators of vulnerable plaque lesions visualized by MRI. In addition, MRI imaging techniques offer other important information on the disease process like inflammation and neovascularization.

In the past decades, a great deal of technical improvements in MR imaging developments has been seen in carotid and aortic studies. Due to the technical difficulties of inherent motion coronary arteries assessment through MRI remains a challenge. However, data on coronary artery wall MR imaging has grown and provides useful clinical information plaque burden and positive arterial remodeling on therapeutic strategies and risk stratification. Research efforts are continually working to address these challenges. Developments in new cardiovascular imaging modalities provide the ability to track and quantify molecular biomarkers. Currently, molecular MR contrast agents and PET-MR are new fields of interests that show promising results on predicting clinical events and monitoring response to therapy. In conclusion, the rapid advancements of magnetic resonance imaging technology provide vast clinical opportunities for diagnosis, prevention, and treatment of atherosclerosis.
Acknowledgements

The first and second authors would like to express their extreme gratitude to Dr. Venkatesh Mani for his patience.

References


Agents with a Prominent Receptor-Induced Magnetization Enhancement We thank Dr. Shikumar Nair for helpful discussions. Angew Chem Int Ed Engl 40: 2303-2306.


